Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization
- 21 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (5) , 699-708
Abstract
No abstract availableKeywords
Funding Information
- Sirtex Medical
This publication has 33 references indexed in Scilit:
- 99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic RadioembolizationJournal of Nuclear Medicine, 2013
- Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheresEJNMMI Research, 2013
- Factors Predicting Response and Survival After Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver MetastasesAnnals of Surgery, 2010
- Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular CarcinomaJAMA, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot StudyJournal of Vascular and Interventional Radiology, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratioJournal of Translational Medicine, 2007